Drug Profile

Coronary tissue engineered vessel - Humacyte

Latest Information Update: 05 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Humacyte
Class Tissue transplantation therapies
Mechanism of Action Tissue replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Coronary artery disease

Most Recent Events

27 Jul 2026 The US FDA accepts the IND application for the first-in-human clinical study of Coronary Tissue Engineered Vessel
27 Jul 2026 Pharmacodynamics data from a preclinical trial in Coronary Artery Bypass Grafting released by Humacyte
12 Nov 2025 Humacyte plans to initiate a phase IIa trial of Coronary Tissue Engineered Vessel for Coronary artery bypass grafting in Q3 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com